Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer

European Urology

Volumn 73, Issue 5, 2018, Pages 727-735

  Zhu, Yezi ^a   Sharp, Adam ^b,c   Anderson, Courtney M ^d   Silberstein, John L ^a   Taylor, Maritza ^a   Lu, Changxue ^a   Zhao, Pei ^a   De Marzo, Angelo M ^a   Antonarakis, Emmanuel S ^a   Wang, Mindy ^d   Wu, Xingyong ^d   Luo, Yuling ^d   Su, Nan ^d   Nava Rodrigues, Daniel ^b   Figueiredo, Ines ^b   Welti, Jonathan ^b   Park, Emily ^d   Ma, Xiao Jun ^d   Coleman, Ilsa ^e   Morrissey, Colm ^f   Plymate, Stephen R ^f   Nelson, Peter S ^e,f   de Bono, Johann S ^b,c   Luo, Jun ^a   more..

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d Advanced Cell Diagnostics Inc   (United States)

^e USA   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Androgen receptor; AR V7; RNA in situ hybridization; Splice variant

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; ENZALUTAMIDE; PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN; ISOPROTEIN;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE BURDEN; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE BIOPSY; TREATMENT OUTCOME; TUMOR BIOPSY; AGED; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; GENETICS; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NEEDLE BIOPSY; PATHOLOGY; PROCEDURES; PROGNOSIS; STATISTICAL MODEL; SURVIVAL ANALYSIS; TUMOR INVASION;

AGED; ANDROGEN ANTAGONISTS; BIOPSY, NEEDLE; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN ISOFORMS; RECEPTORS, ANDROGEN; SURVIVAL ANALYSIS;

EID: 85028507741     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2017.08.009     Document Type: Article

References (28)

1. Antonarakis, E.S., Armstrong, A.J., Dehm, S.M., Luo, J., Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting. Prostate Cancer Prostatic Dis 19 (2016), 231–241.
2. Sharp, A., Welti, J., Blagg, J., de Bono, J.S., Targeting androgen receptor aberrations in castration-resistant prostate cancer. Clin Cancer Res 22 (2016), 4280–4282.
3. Hu, R., Dunn, T.A., Wei, S., et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69 (2009), 16–22.
4. Qu, Y., Dai, B., Ye, D., et al. Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer. Sci Rep, 5, 2015, 7654.
5. Hörnberg, E., Ylitalo, E.B., Crnalic, S., et al. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One, 6, 2011, e19059.
6. Efstathiou, E., Titus, M., Wen, S., et al. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol 67 (2015), 53–60.
7. Steinestel, J., Luedeke, M., Arndt, T., et al. Detecting predictive androgen receptor modifications in circulating prostate cancer cells. Oncotarget 23 (2015), 1–11.
8. Welti, J., Rodrigues, D.N., Sharp, A., et al. Analytical validation and clinical qualification of a new immunohistochemical assay for androgen receptor splice variant-7 protein expression in metastatic castration-resistant prostate cancer. Eur Urol 70 (2016), 599–608.
9. Antonarakis, E.S., Lu, C., Luber, B., et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol 1 (2015), 582–591.
10. Antonarakis, E.S., Lu, C., Wang, H., et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371 (2014), 1028–1038.
11. Onstenk, W., Sieuwerts, A.M., Kraan, J., et al. Efficacy of cabazitaxel in castration-resistant prostate cancer is independent of the presence of AR-V7 in circulating tumor cells. Eur Urol 68 (2015), 939–945.
12. Del Re, M., Biasco, E., Crucitta, S., et al. The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients. Eur Urol 71 (2017), 680–687.
13. Qu, F., Xie, W., Nakabayashi, M., et al. Association of AR-V7 and prostate-specific antigen RNA levels in blood with efficacy of abiraterone acetate and enzalutamide treatment in men with prostate cancer. Clin Cancer Res 23 (2017), 726–734.
14. Todenhofer, T., Azad, A., Stewart, C., et al. AR-V7 transcripts in whole blood RNA of patients with metastatic castration resistant prostate cancer correlate with response to abiraterone acetate. J Urol 197 (2017), 135–142.
15. v567es in patients with prostate cancer. J Urol 196 (2016), 1758–1763.
16. Luo, J., Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer. Asian J Androl 18 (2016), 580–585.
17. Lokhandwala, P.M., Riel, S.L., Haley, L., et al. Analytical validation of androgen receptor splice variant 7 detection in a Clinical Laboratory Improvement Amendments (CLIA) laboratory setting. J Mol Diagn 19 (2017), 115–125.
18. Levsky, J.M., Singer, R.H., Fluorescence in situ hybridization: past, present and future. J Cell Sci 116 (2003), 2833–2838.
19. Speel, E.J., Hopman, A.H., Komminoth, P., Tyramide signal amplification for DNA and mRNA in situ hybridization. Methods Mol Biol 326 (2006), 33–60.
20. Wang, F., Flanagan, J., Su, N., et al. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn 14 (2012), 22–29.
21. Guedes, L.B., Morais, C.L., Almutairi, F., et al. Analytic validation of RNA in situ hybridization (RISH) for AR and AR-V7 expression in human prostate cancer. Clin Cancer Res 22 (2016), 4651–4663.
22. Saylor, P.J., Lee, R.J., Arora, K.S., et al. Branched chain RNA in situ hybridization for androgen receptor splice variant AR-V7 as a prognostic biomarker for metastatic castration-sensitive prostate cancer. Clin Cancer Res 23 (2017), 363–369.
23. Kohli, M., Ho, Y., Hillman, D.W., et al. Androgen receptor variant AR-V9 is co-expressed with AR-V7 in prostate cancer metastases and predicts abiraterone resistance. Clin Cancer Res 23 (2017), 4704–4715.
24. Scher, H.I., Lu, D., Scgreiber, N.A., et al. Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol 2 (2016), 1441–1449.
25. Antonarakis, E.S., Lu, C., Luber, B., et al. Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide. J Clin Oncol 35 (2017), 2149–2156.
26. Robinson, D., Van Allen, E.M., Wu, Y.M., et al. Integrative clinical genomics of advanced prostate cancer. Cell 161 (2015), 1215–1228.
27. Kumar, A., Coleman, I., Morrissey, C., et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med 22 (2016), 369–378.
28. Ferraldeschi, R., Welti, J., Powers, M.V., et al. Second-generation HSP90 inhibitor onalespib blocks mRNA splicing of androgen receptor variant 7 in prostate cancer cells. Cancer Res 76 (2016), 2731–2742.